These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 25585249)

  • 21. Somatic driver mutations in melanoma.
    Reddy BY; Miller DM; Tsao H
    Cancer; 2017 Jun; 123(S11):2104-2117. PubMed ID: 28543693
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oncogenic mutations in melanomas and benign melanocytic nevi of the female genital tract.
    Tseng D; Kim J; Warrick A; Nelson D; Pukay M; Beadling C; Heinrich M; Selim MA; Corless CL; Nelson K
    J Am Acad Dermatol; 2014 Aug; 71(2):229-36. PubMed ID: 24842760
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Melanoma.
    Schadendorf D; Fisher DE; Garbe C; Gershenwald JE; Grob JJ; Halpern A; Herlyn M; Marchetti MA; McArthur G; Ribas A; Roesch A; Hauschild A
    Nat Rev Dis Primers; 2015 Apr; 1():15003. PubMed ID: 27188223
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intra-patient Heterogeneity of BRAF and NRAS Molecular Alterations in Primary Melanoma and Metastases.
    Pellegrini C; Cardelli L; Padova M; Nardo LD; Ciciarelli V; Rocco T; Cipolloni G; Clementi M; Cortellini A; Ventura A; Leocata P; Fargnoli MC
    Acta Derm Venereol; 2020 Jan; 100(1):adv00040. PubMed ID: 31774543
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
    Yaman B; Akalin T; Kandiloğlu G
    Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted therapies in melanoma beyond BRAF: targeting NRAS-mutated and KIT-mutated melanoma.
    Delyon J; Lebbe C; Dumaz N
    Curr Opin Oncol; 2020 Mar; 32(2):79-84. PubMed ID: 31833955
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NRAS mutations are more prevalent than KIT mutations in melanoma of the female urogenital tract--a study of 24 cases from the Netherlands.
    van Engen-van Grunsven AC; Küsters-Vandevelde HV; De Hullu J; van Duijn LM; Rijntjes J; Bovée JV; Groenen PJ; Blokx WA
    Gynecol Oncol; 2014 Jul; 134(1):10-4. PubMed ID: 24802725
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BRAF, NRAS, KIT, TERT, GNAQ/GNA11 Mutation Profile and Histomorphological Analysis of Anorectal Melanomas: A Clinicopathologic Study.
    Taskin OC; Sari SO; Yilmaz I; Hurdogan O; Keskin M; Buyukbabani N; Gulluoglu M
    Turk Patoloji Derg; 2023; 39(1):23-30. PubMed ID: 35642348
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Gene abnormalities in melanoma and signal transduction antagonists].
    Takada M
    Gan To Kagaku Ryoho; 2013 Apr; 40(4):453-7. PubMed ID: 23894754
    [No Abstract]   [Full Text] [Related]  

  • 30. Metastatic Malignant Melanoma With Complete Loss of Differentiation Markers (Undifferentiated/Dedifferentiated Melanoma): Analysis of 14 Patients Emphasizing Phenotypic Plasticity and the Value of Molecular Testing as Surrogate Diagnostic Marker.
    Agaimy A; Specht K; Stoehr R; Lorey T; Märkl B; Niedobitek G; Straub M; Hager T; Reis AC; Schilling B; Schneider-Stock R; Hartmann A; Mentzel T
    Am J Surg Pathol; 2016 Feb; 40(2):181-91. PubMed ID: 26448190
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MAP kinase pathway gene copy alterations in NRAS/BRAF wild-type advanced melanoma.
    Orouji E; Orouji A; Gaiser T; Larribère L; Gebhardt C; Utikal J
    Int J Cancer; 2016 May; 138(9):2257-62. PubMed ID: 26684394
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [New treatment options for metastatic melanoma].
    Tietze JK; Berking C
    Dtsch Med Wochenschr; 2014 Jul; 139(28-29):1462-7. PubMed ID: 24983194
    [No Abstract]   [Full Text] [Related]  

  • 33. Mutations in the BRAF, NRAS, and C-KIT Genes of Patients Diagnosed with Melanoma in Colombia Population.
    Gutiérrez-Castañeda LD; Gamboa M; Nova JA; Pulido L; Tovar-Parra JD
    Biomed Res Int; 2020; 2020():2046947. PubMed ID: 32775409
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [ Spectrum of oncogene mutations is different in melanoma subtypes].
    Mazurenko NN; Tsyganova IV; Lushnikova AA; Ponkratova DA; Anurova OA; Cheremushkin EA; Mikhailova IN; Demidov LV
    Mol Biol (Mosk); 2015; 49(6):1022-9. PubMed ID: 26710785
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment implications of the emerging molecular classification system for melanoma.
    Romano E; Schwartz GK; Chapman PB; Wolchock JD; Carvajal RD
    Lancet Oncol; 2011 Sep; 12(9):913-22. PubMed ID: 21349766
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detecting mechanisms of acquired BRAF inhibitor resistance in melanoma.
    Lo RS; Shi H
    Methods Mol Biol; 2014; 1102():163-74. PubMed ID: 24258979
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytogenetic and mutational analyses of melanocytic tumors.
    Gerami P; Busam KJ
    Dermatol Clin; 2012 Oct; 30(4):555-66, v. PubMed ID: 23021045
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted therapy for melanoma: rational combinatorial approaches.
    Kwong LN; Davies MA
    Oncogene; 2014 Jan; 33(1):1-9. PubMed ID: 23416974
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metastatic melanoma of unknown primary resembles the genotype of cutaneous melanomas.
    Egberts F; Bergner I; Krüger S; Haag J; Behrens HM; Hauschild A; Röcken C
    Ann Oncol; 2014 Jan; 25(1):246-50. PubMed ID: 24276025
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BRAF, KIT, and NRAS Mutations of Acral Melanoma in White Patients.
    Dika E; Veronesi G; Altimari A; Riefolo M; Ravaioli GM; Piraccini BM; Lambertini M; Campione E; Gruppioni E; Fiorentino M; Melotti B; Ferracin M; Patrizi A
    Am J Clin Pathol; 2020 Apr; 153(5):664-671. PubMed ID: 32017841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.